… utility of proteasome inhibitors as synergistic partners in combination regimens with various
… It looks at the potential mechanisms of resistance to proteasome inhibition, and how these …

… However, emerging drug resistance poses a major challenge for clinicians to … proteasome
inhibitors. In this editorial, we discuss proteasome β5-subunit mutations as a novel resistant …

… Multiple myeloma (MM) is an incurable malignancy of plasma cells that generally occurs in
older individuals with a median age at diagnosis of 69 years and a median overall survival of …

… proteasome inhibitor bortezomib (BTZ) significantly improved the prognosis of patients with
multiple myeloma (… BTZ therapy are frequent, while primary resistance to this agent remains a …

… It is the consequence to adaptive mechanisms to circumvent homeostatic issues posed by
proteasome inhibition. Paradoxically, 19S regulator knockdown induced resistance to PIs in …

… the β2-inhibitor LU-102. By contrast, carfilzomib resistant MM cell lines were not sensitive
to combined β5/β2 proteasome inhibition, although CFZ-resistant primary malignant plasma …

… with resistance to proteasome inhibitors, and demonstrate that similar to C-MAF … proteasome
inhibitor resistance, protein stabilization underlies MAFb resistance to proteasome inhibitors…

… In addition to its role as an oncogene in MM, we hypothesize that high MAF protein confers
innate resistance to Bzb. We demonstrate that resistance to proteasome inhibitors (PIs) is …

… proteasome inhibitor (PI) bortezomib (BTZ), a boronic acid derivative, marked the beginning
of a new era of multiple myeloma (… lines are cross-resistant to other proteasome inhibitors. …

… mechanisms of action of proteasome inhibitors that underlie their … mechanisms of resistance
to proteasome inhibition such as … the success and failure of proteasome inhibition in MM for …